隔日投与するプレドニゾンは,システィック線維症の罹患率を低減し,肺機能を改善します
Lancet (London, England)
|September 28, 1985
まとめ
代替日のプレドニゾン療法により,肺機能が有意に改善され,システィック線維症 (CF) の小児の4年間の入院数は副作用なく減少しました.
科学分野:
- 小児科は小児科です.
- 肺内科 肺内科 肺内科
- 薬理学 薬理学とは
背景:
- 胞性線維症 (Cystic Fibrosis,CF) は,複数の臓器,主に肺に影響を与える遺伝疾患です.
- 肺疾患の進行および関連する罹患率は,小児CF患者において重大な懸念事項である.
- 病気の進行を遅らせるための治療戦略を最適化することは極めて重要です.
研究 の 目的:
- CFの小児における肺疾患の進行の管理における,交代的な日のプレドニゾン療法の有効性を評価する.
- CF患者の様々な臨床的および生理学的パラメータに対するプレドニゾンの影響を評価する.
- この集団において,長期にわたって交互に服用するプレドニゾンの安全性プロフィールを決定する.
主な方法:
- ランダム化,ダブルブラインド,プラセボ対照試験が行われました.
- 参加者は,ベースラインで軽度から中等度の肺疾患を有する小児患者 (1~12歳) でした.
- 患者は4年間,交代日プレドニゾンまたはプラセボを投与された.
主要な成果:
- プレドニソンを投与された患者は,プラセボと比較して身長,体重,生命力,FEV1,ピークフロー率,ESR,および血清IgGの有意な改善を示しました.
- CFに関連した肺疾患の入院率は,プレドニゾン群 (9件) とプラセボ群 (35件) の間で大幅に低かった.
- 研究期間中,ステロイドによる有意な副作用は観察されなかった.
結論:
- 代替日のプレドニゾン療法は,小児CF患者の臨床結果を改善し,肺の悪化を軽減するための効果的な治療法です.
- この治療は,4年以上にわたって有害な影響が認められず,好ましい安全性プロファイルを示しています.
- この治療アプローチは,システィック線維症における肺疾患の進行を管理するための有望な戦略を提供します.
さらに関連する動画
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
関連する概念動画
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
